Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · DEFA14A

Bio-Techne Corp

TECHNASDAQEQUITYCurrent

SEC Filing

Filed Sep 9, 2026Accepted Sep 9, 2026, 5:08 PM EDTCIK 842023Accession 0001140361-26-036072
Share

Company context

Bio Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer focused brands: R&D Systems™, Bio Techne Spatial™, and Bio Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

Current securities

Recent company filings

  1. Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureSep 23, 2026
  2. DEFA14A filingSep 14, 2026
  3. Other EventsSep 14, 2026
  4. DEFA14A filingSep 2, 2026
  5. DEFA14A filingAug 25, 2026

As-filed source

Primary evidence